Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors.
A comparison has been made of [(123)I]meta-iodobenzylguanidine ([(123)I]MIBG) and [(111)In]pentetreotide scintigraphy in 54 patients with a variety of neuroendocrine tumors of whom 46 patients had metastatic disease. [(111)In]Pentetreotide scintigraphy was more sensitive in detecting metastatic lesi...
Autors principals: | Kaltsas, G, Korbonits, M, Heintz, E, Mukherjee, J, Jenkins, P, Chew, S, Reznek, R, Monson, J, Besser, G, Foley, R, Britton, K, Grossman, AB |
---|---|
Format: | Journal article |
Idioma: | English |
Publicat: |
2001
|
Ítems similars
-
Treatment of metastatic pheochromocytoma and paraganglioma with I-131-meta-iodobenzylguanidine (MIBG)
per: Kaltsas, G, et al.
Publicat: (2003) -
Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG].
per: Mukherjee, J, et al.
Publicat: (2001) -
Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours.
per: Kaltsas, G, et al.
Publicat: (2004) -
Ocular metastases secondary to carcinoid tumors: the utility of imaging with [(123)I]meta-iodobenzylguanidine and [(111)In]DTPA pentetreotide.
per: Isidori, A, et al.
Publicat: (2002) -
Imaging neuroendocrine tumours with radiolabelled somatostatin analogues and X-ray computed tomography: a comparative study.
per: King, C, et al.
Publicat: (1993)